# The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation

> **NCT00181142** · PHASE2,PHASE3 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 60 (—)

## Conditions studied

- Patients Active and Listed for Lung Transplantation

## Interventions

- **DRUG:** Zenapax

## Key facts

- **NCT ID:** NCT00181142
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-10
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 60 (—)
- **Last updated:** 2017-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00181142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00181142, "The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00181142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*